Safety, tolerability, and pharmacokinetic of HY0721 in Chinese healthy subjects: A first-in-human randomized, double-blind, placebo-controlled dose escalation phase I study

耐受性 药代动力学 安慰剂 医学 药理学 不利影响 内科学 病理 替代医学
作者
Mengyu Zhang,Runhan Liu,Ying Wang,Xiaohong Zhu,Zhenlei Wang,Xiaoyu Li,Li Zheng
出处
期刊:European Journal of Pharmaceutical Sciences [Elsevier BV]
卷期号:200: 106832-106832 被引量:3
标识
DOI:10.1016/j.ejps.2024.106832
摘要

BACKGROUND: HY0721 is a novel inhibitor of sulfonylurea receptor 1-transient receptor potential melastatin 4 (SUR1-TRPM4) for the treatment of acute ischemic stroke. This study aimed to evaluate the safety, tolerability, and pharmacokinetic (PK) profiles of single and multiple intravenous administration of HY0721 in Chinese healthy subjects. METHODS: The study enrolled 48 and 30 healthy volunteers in the single-ascending dose (SAD) cohort (20, 60, 120, 240, and 320 mg) and multiple-ascending dose (MAD) cohort (60, 120, and 160 mg/bid), respectively, to receive the corresponding dosage of HY0721 or placebo. Safety monitoring included but was not limited to recording adverse events (AEs), vital signs, electrocardiograms, and laboratory tests. The blood samples were collected from subjects to determine the concentrations of HY0721 for PK evaluation. RESULTS: The administration of HY0721 showed good safety and tolerability up to 320 mg in the SAD study and up to 160 mg twice daily in the MAD study. The most common AE was injection site reaction, and no AE led to discontinuation of administration or subject dropout. The exposures of HY0721 increased greater than dose proportional manner at the dosages of 20 to 320 mg in the SAD study. A linear PK profile was observed following multiple doses ranging from 60 to 160 mg twice daily, with no evidence of accumulation. Additionally, the human effective dose of HY0721 was estimated to be 120 mg. CONCLUSION: This study demonstrated the intravenous administration of HY0721 is safe and well-tolerated in Chinese healthy subjects and provided 60 to 160 mg b.i.d. as the recommended dosing range for further clinical trials. TRIAL REGISTRATION: ChinaDrugTrials.Org.cn; No. CTR20202604, 18 December 2020.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
所所的应助被刻苦的鸵鸟采纳,获得10
刚刚
刚刚
11完成签到,获得积分10
刚刚
1秒前
曾经寒香发布了新的文献求助10
1秒前
1秒前
星辰大海的应助被yayali采纳,获得10
1秒前
1秒前
喜悦桥发布了新的文献求助10
1秒前
1秒前
genius_yue发布了新的文献求助10
2秒前
rui完成签到,获得积分10
2秒前
桐桐的应助被高手的皇上采纳,获得10
2秒前
zy发布了新的文献求助10
2秒前
平常亦凝完成签到,获得积分10
2秒前
2秒前
虾哥发布了新的文献求助10
3秒前
看不懂文献完成签到,获得积分10
3秒前
曙光发布了新的文献求助10
3秒前
11发布了新的文献求助10
3秒前
脑洞疼的应助被大脚仙采纳,获得10
4秒前
4秒前
Ambt丨on完成签到,获得积分10
4秒前
4秒前
123完成签到,获得积分10
4秒前
5秒前
Xk完成签到 ,获得积分20
5秒前
nana发布了新的文献求助10
5秒前
5秒前
充电宝的应助被zmlle采纳,获得10
6秒前
旺旺发布了新的文献求助10
6秒前
慕青的应助被胡萝卜卜采纳,获得10
6秒前
赘婿的应助被Wenlia采纳,获得10
6秒前
6秒前
mostspecial发布了新的文献求助30
6秒前
声声慢发布了新的文献求助10
7秒前
俊逸的问兰完成签到,获得积分10
7秒前
共享精神的应助被milv5采纳,获得10
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162816
求助须知:如何正确求助?哪些是违规求助? 9557103
关于积分的说明 21738393
捐赠科研通 7753330
什么是DOI,文献DOI怎么找? 3427963
关于科研通互助平台的介绍 2552742
邀请新用户注册赠送积分活动 2472556